Frost & Sullivan: TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs

Frost & Sullivan: TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs PR Newswire MOUNTAIN VIEW, California, Dec. 5, 2012 -- Huge market potential drives pharmaceutical and biotechnology companies to develop affordable alternatives with superior efficacy MOUNTAIN VIEW, California, Dec. 5, 2012 /PRNewswire/ -- The challenges inherent in the pharmacological management of rheumatic diseases have stoked huge demand for drug classes with excellent safety and efficacy profiles. While tumor necrosis factor (TNF) inhibitors have greatly enhanced the treatment of these incurable chronic conditions, their unpredictable and inconsistent efficacy as well as their high cost, potential side effects, and uncomfortable mode of delivery (by injection) are driving the need for alternative therapies. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com/) The United States Rheumatic Diseases Therapeutics Market research finds that rheumatic disease therapeutics prescribed as add-on therapies to background standard therapies earned revenues of approximately $8.99 billion in 2011 and estimates this to reach $14.04 billion by 2017. Frost & Sullivan has also analyzed sub-segments of the U.S. rheumatic diseases therapeutics market, including psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis pharmacotherapeutics.